Charles River to Buy Frontage Bioanalysis and DMPK Businesses

Charles River Laboratories has agreed to acquire Frontage Holdings’ bioanalysis and drug metabolism and pharmacokinetics (DMPK) businesses in Exton, Pennsylvania, for approximately $470 million in cash, with an additional $75 million in potential performance-based payments.

The acquisition includes two laboratory sites spanning approximately 150,000 square feet and employing about 340 people. The facilities provide bioanalysis, biomarker and DMPK testing services for large and small molecules, primarily supporting clinical development programs for biopharmaceutical companies. The operations also include a Clinical Laboratory Improvement Amendments (CLIA)-certified central laboratory.

The deal will expand Charles River’s clinical bioanalysis capabilities, complementing its existing strength in preclinical testing, particularly for biologics and complex modalities. The company said the combined capabilities will provide more continuous testing support as drug candidates advance from preclinical research into clinical development.

The transaction is expected to close in the first half of 2027, subject to shareholder, regulatory and other customary approvals. The acquired businesses will become part of Charles River’s Discovery and Safety Assessment segment.

 

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers from Tablets & Capsules – all delivered right to your inbox! Sign up now!